ACG

ATA Creativity Global Reports 2023 Fourth Quarter and Year-end Financial Results

Retrieved on: 
Tuesday, March 26, 2024
ACG, Student, Travel, COVID, Marketing, Research, ADS, Pharmaceutical industry

Gross profit for Fourth Quarter 2023 was RMB52.4 million (US$7.4 million), an increase of 10.0% from RMB47.6 million in the prior-year period, primarily due to increased revenues during the period.

Key Points: 
  • Gross profit for Fourth Quarter 2023 was RMB52.4 million (US$7.4 million), an increase of 10.0% from RMB47.6 million in the prior-year period, primarily due to increased revenues during the period.
  • Total operating expenses for Fourth Quarter 2023 were RMB43.3 million (US$6.1 million), compared to RMB42.7 million in the prior-year period.
  • Income from operations for Fourth Quarter 2023 was RMB9.1 million (US$1.3 million), an increase of 86.1% from RMB4.9 million in the prior-year period.
  • Net income attributable to ACG for Fourth Quarter 2023 increased 324.1% to RMB8.6 million (US$1.2 million), from net income attributable to ACG of RMB2.0 million in the prior-year period.

Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, March 21, 2024
Research, Ulcerative colitis, ECCO, LTE, ACG, Patient, UC, Journal, Biomarker, NEXUS, Wind, Insurance, Abstract, American College, Clinical trial, Safety, Pharmacokinetics, Poster, NLRX1, European, PLXDC2, Pharmaceutical industry

NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or “the Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and reported financial results for the fourth quarter and the full year ended December 31, 2023.

Key Points: 
  • NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or “the Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and reported financial results for the fourth quarter and the full year ended December 31, 2023.
  • Top-line results are planned for the fourth quarter of 2024.
  • Research and development expenses were $3.1 million for the fourth quarter of 2023, compared to $3.4 million for the fourth quarter of 2022.
  • General and administrative expenses were $3.5 million for the fourth quarter of 2023, compared to $3.1 million for the fourth quarter of 2022.

Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 14, 2024
Research, Certification, Quarter, Prevalence, Teva Pharmaceuticals, Gastrointestinal disease, Partnership, ACG, Metoclopramide, Patient, Pharmacy, Gastroparesis, Health care, Holocene, Prescription, Orange Book, Marketing, Gastroenterology, Woman, DDW, PBM, Hospital, Pharmaceutical industry

SOLANA BEACH, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the fourth quarter and full year ended December 31, 2023, and recent corporate developments.

Key Points: 
  • Our commercial team’s dedicated efforts yielded a 107% increase in year-over-year revenue,” stated Dave Gonyer, R.Ph., CEO of Evoke Pharma.
  • Research and development expenses totaled approximately $23,000 for the fourth quarter of 2023 compared with $27,000 for the fourth quarter of 2022.
  • For the fourth quarter of 2023 selling, general and administrative (SG&A) expenses were approximately $3.5 million compared with $2.3 million for the fourth quarter of 2022.
  • Total operating expenses for the fourth quarter of 2023 were approximately $3.6 million compared with $2.3 million for the same period of 2022.

Aviation Capital Group Announces Delivery of One A321neo to SKY Airline

Retrieved on: 
Friday, April 5, 2024
Professional Services, Air, Transport, Finance, CFM International, Sky Airline, CFO, Partnership, ACG, Airbus, Aviation, A320, Pacific Life, Multimedia, Sky Airlines, Airbus A320neo family, Airbus A320 family, Capital Group Companies, Airline

Aviation Capital Group LLC (ACG), a premier global full-service aircraft asset manager, announced the delivery of one new Airbus A321neo aircraft on long-term lease to SKY Airline.

Key Points: 
  • Aviation Capital Group LLC (ACG), a premier global full-service aircraft asset manager, announced the delivery of one new Airbus A321neo aircraft on long-term lease to SKY Airline.
  • Featuring CFM International LEAP-1A engines, this is the first of two aircraft scheduled to deliver to the airline.
  • View the full release here: https://www.businesswire.com/news/home/20240405651549/en/
    Airbus A321neo Leased by Aviation Capital Group to SKY Airlines.
  • (Photo: Business Wire)
    “We are very happy to support SKY Airline with the delivery of this A321neo, enabling it to expand its network and to have one of the most modern fleets in the Americas.

NIMML Institute’s TITAN-X A.I.-Powered Precision Medicine Platform Validated through AbbVie’s Acquisition of Landos Biopharma and Lead Clinical Candidate NX-13

Retrieved on: 
Monday, March 25, 2024
Health, Health Technology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, AbbVie, Ulcerative colitis, Growth, I&I, Cell, ACG, Patient, ABBV, UC, Journal, Biomarker, NIMML, Acquisition, LANCL2, IPO, SLE, Personalized medicine, Volunteering, A.I, IBD, Medicine, Rheumatoid arthritis, Epithelium, DRS, Invention, Therapy, NLRX1, Work, Pharmaceutical industry

and computational modeling capabilities were instrumental for the characterization of NLRX1 as a therapeutic target for autoimmune diseases and the development of NX-13.

Key Points: 
  • and computational modeling capabilities were instrumental for the characterization of NLRX1 as a therapeutic target for autoimmune diseases and the development of NX-13.
  • “Importantly, AbbVie is one of the world’s largest biopharma companies with an incredibly successful I&I franchise that it has built over the last two decades.
  • In addition to Landos Biopharma, Dr. Bassaganya-Riera founded NImmune Biopharma (“NImmune”) with the purpose to advance the clinical development of the LANCL2 portfolio of immunoregulatory precision medicines.
  • Both omilancor and NIM-1324 are guided by precision biomarkers discovered and developed by NIMML’s TITAN-X A.I.-powered Precision Medicine platform.

Aviation Capital Group Announces Delivery of One A320-200 to Canada Jetlines

Retrieved on: 
Monday, March 18, 2024
Finance, Air, Professional Services, Transport, Asset Management, ACG, Partnership, Airbus, Marketing, Aviation, A320-200, Capital Group Companies, Airline

Aviation Capital Group LLC (“ACG”), a premier global full-service aircraft asset manager, announced the delivery of one Airbus A320-200 on long-term lease to Canada Jetlines Operations Ltd. (“Canada Jetlines”).

Key Points: 
  • Aviation Capital Group LLC (“ACG”), a premier global full-service aircraft asset manager, announced the delivery of one Airbus A320-200 on long-term lease to Canada Jetlines Operations Ltd. (“Canada Jetlines”).
  • “ACG is proud to broaden its footprint in North America and is pleased to welcome Canada Jetlines as a new lessee,” said Alan Mangels, Vice President of Marketing for ACG.
  • “We look forward to this new, long-term partnership.”
    “Canada Jetlines is delighted to join forces with ACG as we continue to strengthen our fleet and expand our reach,” said Eddy Doyle, CEO of Canada Jetlines.
  • In addition to aircraft leasing services, ACG provides aircraft asset management solutions tailored to meet our customers’ fleet management needs.

Brand Velocity Group Hires Daniel Hodges as Principal

Retrieved on: 
Monday, March 11, 2024
General Sports, Sports, Finance, Marketing, Communications, Business, Professional Services, Fashion, Retail, ACG, MBA, Shake Shack, Duke University, Columbia Business School, BVG, The Carlyle Group, Partner (business rank), SKIMS, Industrial design

Brand Velocity Group (“BVG”), an innovative and diversified investment platform focused on acquiring and transforming businesses, today announced that Daniel Hodges has joined the firm as a Principal.

Key Points: 
  • Brand Velocity Group (“BVG”), an innovative and diversified investment platform focused on acquiring and transforming businesses, today announced that Daniel Hodges has joined the firm as a Principal.
  • Based in New York, Hodges will focus on sourcing and executing new investment opportunities, as well as working closely to enhance the value of BVG’s existing portfolio companies.
  • Hodges joins BVG from Alliance Consumer Growth (“ACG”) where he was a Principal responsible for deal sourcing and execution, and portfolio company oversight.
  • I look forward to collaborating with exceptional business owners who are looking for solutions beyond the typical private equity ‘playbook’,” said Hodges.

ATEL Capital Group Expands Team to Support Growth

Retrieved on: 
Thursday, April 4, 2024
Apple Inc., Growth, ACG, Cornell University, SAN, Notre Dame Law School, University, Senior counsel, MBA, Counsel, Silicon, Fortune 1000, Silicon Valley Bank, Private law, VCS, Structural capital, Lawyer, Financial services

SAN FRANCISCO, April 4, 2024 /PRNewswire/ -- ATEL Capital Group (ACG), a multi-billion dollar financial services firm focusing on venture debt, equipment leasing and real estate has announced four new team members as part of its strategy to meet growing demand for debt financing of venture-backed companies and equipment leasing to Fortune 1000 companies.

Key Points: 
  • Todd Jaquez-Fissori joins ATEL Ventures, Inc., a division of ACG, as Senior Vice President.
  • Jaquez-Fissori has almost two decades of experience originating venture debt and private credit deals, most recently with Structural Capital, where he was a Managing Partner, and previously with Tennenbaum Capital Partners, Hercules Growth Capital and TriplePoint Capital.
  • Simrat Wason joins ATEL Ventures, Inc. as a Director.
  • Supporting ATEL Capital Group's increased deal flow is an enlarged legal team.

Aviation Capital Group Announces Delivery of One A321neo to Volaris

Retrieved on: 
Thursday, February 29, 2024
Air, Transport, Other Transport, Airbus, Aviation, Capital Group Companies, Sale, Pratt & Whitney PW1000G, Multimedia, ACG, Pacific Life, Airline

Aviation Capital Group LLC (“ACG”) announced the delivery of one new Airbus A321neo aircraft on long-term lease to Volaris.

Key Points: 
  • Aviation Capital Group LLC (“ACG”) announced the delivery of one new Airbus A321neo aircraft on long-term lease to Volaris.
  • View the full release here: https://www.businesswire.com/news/home/20240229161702/en/
    Airbus A321neo Leased by Aviation Capital Group to Volaris Airlines.
  • In addition to aircraft leasing services, we provide aircraft asset management solutions tailored to meet our customers’ fleet management needs.
  • To learn more about the aircraft leasing and aircraft management services offered by ACG, visit www.aviationcapitalgroup.com .

Agilent Reports First-Quarter Fiscal Year 2024 Financial Results

Retrieved on: 
Tuesday, February 27, 2024
Medical Supplies, Biotechnology, Technology, Health, General Health, Health Technology, Medical Devices, Research, Software, Genetics, Science, Agilent Technologies, ACG, Growth, Diagnosis, Conference, GAAP, Webcast, PST, DGG, Bank statement

“The Agilent team continued its strong execution in the first quarter, delivering better-than-expected revenue and earnings,” said President and CEO Mike McMullen.

Key Points: 
  • “The Agilent team continued its strong execution in the first quarter, delivering better-than-expected revenue and earnings,” said President and CEO Mike McMullen.
  • Fiscal year 2024 non-GAAP(3) earnings guidance is also maintained with a range of $5.44 to $5.55 per share.
  • Agilent’s management will present additional details regarding the company’s first-quarter 2024 financial results on a conference call with investors today at 1:30 p.m. PST.
  • To listen to the webcast, select the “Q1 2024 Agilent Technologies Inc. Earnings Conference Call” link on the Agilent Investor Relations website .